4 research outputs found
Development and Validation of a Specific Stability Indicating High Performance Liquid Chromatographic Method for Valsartan
A stability-indicating HPLC assay method has been developed and validated for valsartan in bulk drug and pharmaceutical dosage forms. An isocratic RP-HPLC was achieved on Waters 2695 using Symmetry C18 (250mm × 4.6mm × 5μ) column with the mobile phase consisting of 0.02 mM sodium dihydrogen ortho-phosphate, pH adjusted to 2.5 using ortho-phosphoric acid (solvent A), and acetonitrile (solvent B) in the ratio of 58:42 %v/v. The stress testing of valsartan was carried out under acidic, alkaline, oxidative, thermal, and photolytic conditions. Valsartan was well resolved from its degradation products. The proposed method was validated as per ICH guidelines. The method was found to be suitable for the quality control of valsartan in bulk and pharmaceutical dosage forms as well as the stability-indicating studies
Multiparticulate Drug Delivery Systems for Controlled Release
Pharmaceutical invention and research are increasingly focusing on
delivery systems which enhance desirable therapeutic objectives while
minimising side effects. Recent trends indicate that multiparticulate
drug delivery systems are especially suitable for achieving controlled
or delayed release oral formulations with low risk of dose dumping,
flexibility of blending to attain different release patterns as well as
reproducible and short gastric residence time. The release of drug from
microparticles depends on a variety of factors including the carrier
used to form the multiparticles and the amount of drug contained in
them. Consequently, multiparticulate drug delivery systems provide
tremendous opportunities for designing new controlled and delayed
release oral formulations, thus extending the frontier of future
pharmaceutical development
Multiparticulate Drug Delivery Systems for Controlled Release
Pharmaceutical invention and research are increasingly focusing on
delivery systems which enhance desirable therapeutic objectives while
minimising side effects. Recent trends indicate that multiparticulate
drug delivery systems are especially suitable for achieving controlled
or delayed release oral formulations with low risk of dose dumping,
flexibility of blending to attain different release patterns as well as
reproducible and short gastric residence time. The release of drug from
microparticles depends on a variety of factors including the carrier
used to form the multiparticles and the amount of drug contained in
them. Consequently, multiparticulate drug delivery systems provide
tremendous opportunities for designing new controlled and delayed
release oral formulations, thus extending the frontier of future
pharmaceutical development